Patients with the highest intra-tumor ERBB1 mRNA expression levels (top 40%, EGFR/ERBB1high) had worse DFS (Supplementary Materials: Figure S7A) and OS (Supplementary Materials: Figure S7B) than patients with the lowest intra-tumor ERBB1 mRNA levels (bottom 40%, EGFR/ERBB1low). This evidence concerns the gene EGFR and neoplasm.